Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3557859 | 0.91 | CHRM3 (0.66) | CHRM3ADRB2 | |
| SCHEMBL3132447 | 0.90 | CHRM3 (0.61) | CHRM3ADRB2 | |
| SCHEMBL3143166 | 0.90 | CHRM3 (0.59) | CHRM3ADRB2 | |
| SCHEMBL644531 | 0.89 | CHRM3 (0.62) | CHRM3ADRB2 | |
| SCHEMBL13430603 | 0.89 | CHRM3 (0.60) | CHRM3ADRB2 | |
| SCHEMBL645370 | 0.89 | CHRM3 (0.67) | CHRM3ADRB2 | |
| SCHEMBL3137874 | 0.88 | CHRM3 (0.56) | CHRM3ADRB2 | |
| SCHEMBL3138369 | 0.88 | CHRM3 (0.58) | CHRM3ADRB2 | |
| SCHEMBL1191254 | 0.87 | CHRM3 (0.67) | CHRM3 | |
| SCHEMBL3134498 | 0.87 | CHRM3 (0.56) | CHRM3ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329911-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-12-11 | — | — | US | claimed |
| US-20100063096-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-03-11 | — | — | US | claimed |
| US-20060205779-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2006-09-14 | — | — | US | claimed |
| US-8329911-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20100063096-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-03-11 | — | — | US | disclosed |
| US-7642355-B2 | Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-(5-[4-(3-dimethylaminopropoxy)benzylamino]pentylcarbamoyl)ethyl)piperidin-4-yl ester | THERAVANCE, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20060205779-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205779-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885ADRB2 17/4885 |
| US-20100063096-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM1, CHRM3 | CHRM3 3/4885ADRB2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.